Japan Diabetes Drugs Market Overview

Market Statistics

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Size in 2024:  USD 4.4 Billion

Market Forecast in 2033: USD 5.9 Billion

Market Growth Rate: 3.5% (2025-2033)

According to the latest report by IMARC Group, the Japanese diabetes drugs market size reached USD 4.4 billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 billion by 2033, exhibiting a growth rate (CAGR) of 3.5% during 2025-2033.

Japan Diabetes Drugs Market Trends and Drivers:

The increase in cases of diabetes and the aging population are the two factors that have led to growth in Japan's diabetes drug market. Moreover, lifestyle changes, increased risk of obesity, and the fast-growing elderly population have turned diabetes into a significant health issue in Japan. It has contributed to the increase in the demand of effective diabetes management drugs such as insulin, oral anti diabetic medicines, and emerging treatment methods, such as GLP-1 receptor agonists and the SGLT-2 inhibitors. The government officials are focusing on better management of diabetes and early diagnosis as well as the improvement in healthcare infrastructure, which is contributing even further to the market. The pharmaceutical firms are also engaged in research and development (R&D) to come up with novel drugs that offer improved glycemic control and with fewer side effects.

The transition to individual medicine solutions and combination therapies is boosting the Japanese diabetes drugs market. Besides this, since diabetes patients are usually characterized by specific needs and comorbidities, an increasing need can be observed to provide individual treatment plans, including a combination of different drug classes, to maximize the effectiveness. Furthermore, the use of digital health devices is increasing medication compliance among patients by making it possible to monitor and intervene before things take the wrong direction. The drugs that have the ability to delay the onset of the complications of diabetes are also in use due to the rising awareness of the role of preventive measures. Other than this, the emergence of insulin products as biosimilars is increasing access to low-cost treatment facilities, which is another factor facilitating the growth of the market. With respect to the future, Japan's diabetes drug market is set to face continuous growth in the coming years due to the persistence of innovation, enhanced accessibility, and emphasis on the prolonged management of diseases.

Download a Sample PDF of This Report: https://www.imarcgroup.com/japan-diabetes-drugs-market/requestsample

Japan Diabetes Drugs Market Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Japan Diabetes Drugs Market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.

The report has segmented the market into the following categories:

• Insulins
  • Basal or Long-Acting Insulins
    • Lantus (Insulin Glargine)
    • Levemir (Insulin Detemir)
    • Toujeo (Insulin Glargine)
    • Tresiba (Insulin Degludec)
    • Basaglar (Insulin Glargine)
  • Bolus or Fast-Acting Insulins
    • NovoRapid/Novolog (Insulin Aspart)
    • Humalog (Insulin Lispro)
    • Apidra (Insulin Glulisine)
  • Traditional Human Insulins
    • Novolin/Actrapid/Insulatard
    • Humulin
    • Insuman
  • Biosimilar Insulins
    • Insulin Glargine Biosimilars
    • Human Insulin Biosimilars
• Oral Anti-diabetic Drugs
  • Biguanides
    • Metformin
  • Alpha-Glucosidase Inhibitors
  • Dopamine D2 Receptor Agonist
    • Bromocriptin
  • SGLT-2 Inhibitor
    • Invokana (Canagliflozin)
    • Jardiance (Empagliflozin)
    • Farxiga/Forxiga (Dapagliflozin)
    • Suglat (Ipragliflozin)
  • DPP-4 Inhibitors
    • Onglyza (Saxagliptin)
    • Tradjenta (Linagliptin)
    • Vipidia/Nesina (Alogliptin)
    • Galvus (Vildagliptin)
  • Sulfonylureas
  • Meglitinides
• Non-Insulin Injectable Drugs
  • GLP-1 Receptor Agonists
    • Victoza (Liraglutide)
    • Byetta (Exenatide)
    • Bydureon (Exenatide)
    • Trulicity (Dulaglutide)
    • Lyxumia (Lixisenatide)
  • Amylin Analogue
    • Symlin (Pramlintide)
• Combination Drugs
  • Insulin Combinations
    • NovoMix (Biphasic Insulin Aspart)
    • Ryzodeg (Insulin Degludec and Insulin Aspart)
    • Xultophy (Insulin Degludec and Liraglutide)
  • Oral Combination
    • Janumet (Sitagliptin and Metformin)

Distribution Channel Insights:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant. Additionally, the report features detailed profiles of all major companies in the Japan Diabetes Drugs industry.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact:
Street: 563-13 Kamien
Area: Iwata
Country: Tokyo, Japan
Postal Code: 4380111
Email: sales@imarcgroup.com